![[Img #75111]](https://thelatestnews.world/wp-content/uploads/2025/02/They-identify-a-link-between-the-immune-system-and-survival.jpg)
Recent research has revealed the existence of a relationship between antitumor immune activity and longevity in breast cancer surviving women. Specifically, the study demonstrates that high levels of an immune profile of 14 genes in tumor samples are associated with a significant reduction in the risk of mortality between patients who have apparently exceeded the disease, maintaining this association regardless of the type of breast cancer and the Patient’s age.
The study has been coordinated by Dr. Fara Brasó-Maristany, researcher at the Translational Genomic Group and therapies directed in solid tumors of the Biomedical Research Institute August Pi I Sunyer (IDIBAPS) in Barcelona, and Dr. Aleix Prat, director of the Institute of cancer and blood diseases of the Clinic Hospital of Barcelona and head of the IDIBAPS group. It has been collided with the Reveal Genomics company and has had the collaboration of numerous research groups, both from Catalonia, and the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (Idibell) in Hospitalet de Llobregat, and The Institute of Oncology of the Vall d’Hebron Hospital (VHIO) in Barcelona, as of the United States, including the LCCC (Lineberger Comprehensive Cancer Center) in Chapel Hill and the HDFCI (Harvard-Dana-Farber Cancer Institute) in Boston.
Previously, the team had demonstrated an association between high levels of IgG in tumors and reducing relapse risk. In this new study and through data analysis of 9,638 patients in three independent cohorts, the research team has found that those who have had breast cancer, have not fallen and their tumors had high levels of IgG, experience a risk reduction of 41-47% mortality compared to those who had tumors with low IgG levels.
Dr. Laura Angelats, oncologist at the Clinic Hospital in Barcelona and researcher at IDIBAPS, highlights the importance of the results as the first author of the study: “Our work shows that the IgG profile goes beyond its previously known role in the detection of recurrences of breast cancer.
Dr. Fara Brasó-Maristany explains that, “this finding not only reinforces the critical role of the immune system in the survival of breast cancer, but also opens the door to new diagnostic tools and treatment strategies. Integrating immunological profiles such as The IGG, we can move towards a truly precision oncology that addresses both the tumor and the patient’s immune response.
From left to right: Carlota Rubio, Laura Angelats, Laia Paré (Reveal Genomics) and Fara Brasó-Maryny, of the research team. (Photo: Clinic Hospital of Barcelona / IDIBAPS)
Integration of unicellular sequencing and immune profile
The study has included new technologies such as the spatial analysis of the immune microenvironment of the tumor. , which has been carried out in collaboration with the OMNISCOPE company, providing in detail the characteristics of each immune cell individually.
These analyzes have revealed the active role of B and T cells, strongly linked to the presence of tertiary lymphoid structures (TLS), specialized immune niches within the tumors associated with antitumor responses. In addition, the sequencing of the TCR cell receptor and the BC cell receiver (BCR) has demonstrated the diversity and activity of adaptive immune responses, offering more evidence of the protective paper of the immune system in patients free of recurrence. These results underline the IgG profile as a integral marker that reflects not only immune infiltration, but also the functional organization of immune responses within tumors.
HER2DX®: A key innovation in precision oncology
The 14-gene immune profile is a central Her2DX® component, the world’s first diagnostic test specifically designed for her2-positive breast cancer. Codesñada by the Hospital Clínic, the IDIBAPS, the University of Padua and the company promoted by the Clinic and VHio campus, Reveal Genomics®, Her2DX® integrates clinical and genomic data to provide a complete evaluation of the risk of relapse, the probability of achieving a Complete pathological response (PCR) to the treatment and expression levels of ERBB2. Clinically validated and already benefiting patients, Her2DX® has become a transforming tool in precision oncology. In recognition of its impact, Time magazine included Her2DX® in its list of the “best inventions” of 2022.
Integrate the biology of the immune system into cancer research
Based on these results, the team will investigate the IgG profile more thoroughly and its implications in breast cancer and other types of cancer. This research aims to deepen the understanding of the role of the immune system in general health and advance in the development of innovative diagnostic and therapeutic strategies.
Dr. Aleix Prat adds: “This study underlines the power of information provided by the immune system by interacting with the tumor. Through our research in breast cancer and other types of cancer, and taking advantage of advanced genomic tools, we aspire to improve both the survival results and the quality of life of those who have had cancer. ”
The study is entitled “Linking Immune Tumor Infiltration to enhanced longevity in recurrence-FREE BREAST CANCER”. And it has been published in the academic magazine Esmo Open. (Source: Barcelona Clinic Hospital / IDIBAPS)
Add Comment